Malignant lymphomas of follicular centre cell origin in man. VII. Prognostic features in small cleaved cell lymphoma.

abstract：:Bone marrow (BM) trephine biopsy is a part of routine staging of patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). The significance of lymphoid monoclonal population on flow cytometry (FC) of the BM aspirate in the presence of negative BM histology has not been clarified. In this study, we assessed ...

journal_title：Hematological oncology

authors： Wolach O,Fraser A,Luchiansky M,Shapiro C,Radnay J,Shpilberg O,Lishner M,Lahav M

更新日期：2015-03-01 00:00:00

abstract：:The acquired clonal disorder Polycythaemia Vera leads to increased erythropoiesis, myelopoiesis and megakaryopoeisis. These anomalies result in an increased incidence of thromboembolic events, transformation to acute leukaemia and myelofibrosis. Treatments which aim to reduce the event rate may increase anaemia but ma...

journal_title：Hematological oncology

authors： McMullin MF

更新日期：2007-06-01 00:00:00

abstract：:Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...

journal_title：Hematological oncology

authors： Sonigo C,Bajeux J,Boubaya M,Eustache F,Sifer C,Lévy V,Grynberg M,Sermondade N

更新日期：2020-10-01 00:00:00

abstract：:Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...

journal_title：Hematological oncology

authors： Tonialini L,Bonfichi M,Ferrero S,Malipiero G,Nozza A,Argnani L,Zinzani PL

更新日期：2018-10-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. The standard therapy for DLBCL is R-CHOP. The current 5-year overall survival is 60% to 70% using standard frontline therapy. However, the use of doxorubicin and its cardiotoxicity is a major clinical problem and preexisting cardiac disease may...

journal_title：Hematological oncology

authors： Prusila REI,Peroja P,Jantunen E,Turpeenniemi-Hujanen T,Kuittinen O

更新日期：2019-04-01 00:00:00

abstract：:This paper presents a new analysis of aspects of the descriptive epidemiology of multiple myeloma (MM) for parts of the U.K., 1984-1993. It provides no indication for geographical heterogeneity, nor is there evidence of a decline in rates over the decade. There is, however, evidence that cancer registration inflates M...

journal_title：Hematological oncology

authors： Cartwright RA,Gilman EA,Nicholson P,Allon D

更新日期：1999-03-01 00:00:00

abstract：:Plasma cholesterol concentrations were determined in 83 acute myeloid leukemia patients. Mean plasma cholesterol concentration (+/- S.D.) at the time of diagnosis was 2.91 mmol/L (+/- 1.13). The percentage of AML patients having hypocholesterolemia was 90.4 per cent. The lowest cholesterol levels were observed in the ...

journal_title：Hematological oncology

authors： Zyada LE,Hassan HT,Rees JK,Ragab MH

更新日期：1990-01-01 00:00:00

abstract：:Acute myeloid leukaemia is a disease with unfavourable prognosis. The significance of various prognostic parameters is not fully understood. We studied 293 patients to examine the influence of ethnicity and molecular markers. The median survival for all patients was correlated with age, white blood cell count and kary...

journal_title：Hematological oncology

authors： Goldschmidt N,Cohen SB,Gatt ME,Safrai M,Rund D

更新日期：2014-06-01 00:00:00

abstract：:One hundred and fifteen previously untreated adults aged over 60 years were referred to St Bartholomew's Hospital between 1978 and 1986 for management of acute myeloid leukemia (AML). Twenty-seven patients received symptomatic or palliative treatment only because combination chemotherapy was considered inappropriate. ...

journal_title：Hematological oncology

authors： Tucker J,Thomas AE,Gregory WM,Ganesan TS,Malik ST,Amess JA,Lim J,Willis L,Rohatiner AZ,Lister TA

更新日期：1990-01-01 00:00:00

abstract：:Recent studies have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). However, there have been few reports on MYC translocation in Chinese patients. One hundred and six cases of DLBCLs were analyzed using interphase fluorescent in s...

journal_title：Hematological oncology

authors： Zhang HW,Chen ZW,Li SH,Bai W,Cheng NL,Wang JF

更新日期：2011-12-01 00:00:00

abstract：:Mucosa-associated lymphoid tissue (MALT) lymphoma is a radiosensitive malignancy. We report on a case of severe retinopathy following radiation therapy with a moderate dose for orbital MALT lymphoma. A 69-year-old woman with orbital MALT lymphoma received definitive radiation therapy with a total dose of 36 Gy in 18 f...

journal_title：Hematological oncology

authors： Hata M,Kaneko A,Tomita N,Inoue T

更新日期：2014-12-01 00:00:00

abstract：:We have collected, by an active retrospective survey, all the cases of hematologic malignancies (HM) newly diagnosed during the time period 1974-1993 in the resident population of Sardinia. Diagnosis was deemed valid, after consultation of clinical records, in more than 90% of the 7264 collected cases. The number of n...

journal_title：Hematological oncology

authors： Broccia G,Deplano W,Dessalvi P,Giannico B,Luxi G,Chessa E,Murru A

更新日期：2004-09-01 00:00:00

abstract：:Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...

journal_title：Hematological oncology

authors： Zamkoff KW,Watman NP,Duggan DB,Poiesz BJ,Gottlieb AJ

更新日期：1990-03-01 00:00:00

abstract：:Post-transplant lymphoproliferative disorders of T-cell origin are quite uncommon, and the vast majority represent neoplasms of mature, post-thymic T- or natural killer cells. Here, we report a rare case of T-cell acute lymphoblastic leukaemia (T-ALL), which occurred in an 18-year-old man who had undergone three liver...

journal_title：Hematological oncology

authors： Fang Y,Pinkney KA,Lee JC,Gindin T,Weiner MA,Alobeid B,Bhagat G

更新日期：2013-03-01 00:00:00

abstract：:One hundred and forty-one consecutive patients above and 231 below the age of 60 years with previously untreated intermediate or high grade non-Hodgkin's lymphoma were included in this study. Patients above the age of 60 years were treated with the COPP chemotherapy regimen. The younger patients, at or below the age o...

journal_title：Hematological oncology

authors： Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho F

更新日期：1993-01-01 00:00:00

abstract：:Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within the last two decades. However, until recently, improvement in overall survival (OS) was only documented in younger, transplant-eligible patients. In this analysi...

journal_title：Hematological oncology

authors： Mey UJ,Leitner C,Driessen C,Cathomas R,Klingbiel D,Hitz F

更新日期：2016-12-01 00:00:00

abstract：:Primary CNS lymphoma (PCNSL) is an aggressive brain tumor that represents a significant challenge both to elucidate its biological pathogenesis as well as to develop definitive precision medicines with minimal collateral toxicity. We highlight the key issues in diagnosis and treatment and focus on emerging technologie...

journal_title：Hematological oncology

authors： Tsang M,Cleveland J,Rubenstein JL

更新日期：2020-12-01 00:00:00

abstract：:Oral mucositis (OM) is one of the side effects of hematopoietic stem cell transplantation (HSCT), resulting in major morbidity. The aim of this study was to determine the cost-effectiveness of the introduction of a specialized oral care program including laser therapy in the care of patients receiving HSCT with regard...

journal_title：Hematological oncology

authors： Bezinelli LM,de Paula Eduardo F,da Graça Lopes RM,Biazevic MG,de Paula Eduardo C,Correa L,Hamerschlak N,Michel-Crosato E

更新日期：2014-03-01 00:00:00

abstract：:Composite plasma cell neoplasm (PCN) and low grade B-cell lymphoma (B-NHL) in the bone marrow are uncommon and raise the differential diagnosis of B-NHL with plasmacytic differentiation and PCN with lymphoplasmacytic morphology. This can be a challenging differential diagnosis, and the distinctions are important becau...

journal_title：Hematological oncology

authors： Hussein S,Gill K,Baer LN,Hoehn D,Mansukhani M,Jobanputra V,Bhagat G,Alobeid B

更新日期：2015-03-01 00:00:00

abstract：:Abdominal presentations of pediatric NHL are rarely amenable to complete surgical resection. Chemotherapy is the hallmark of treatment for pediatric NHL. Treatment of various types of this disease including intra-abdominal NHL in children with various protocols have not exceeded 54 per cent two-year disease-free survi...

journal_title：Hematological oncology

authors： Abdel Hadi SS,el Taneer OM,Hussein MH,el Haddad A,el Badawi S,Mokhtar N,Hamza MR,el Mawla NG

更新日期：1991-07-01 00:00:00

abstract：:The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacit...

journal_title：Hematological oncology

authors： Agarwal S,Gopalakrishnan S,Mensing S,Potluri J,Hayslip J,Kirschbrown W,Friedel A,Menon R,Salem AH

更新日期：2019-10-01 00:00:00

abstract：:Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...

journal_title：Hematological oncology

authors： Kiesewetter B,Lamm W,Neuper O,Mayerhoefer ME,Simonitsch-Klupp I,Raderer M

更新日期：2019-10-01 00:00:00

abstract：:The relationship between myeloblast-like cells and cluster-forming cells detected by growth in agar has been studied in 22 untreated patients with acute non-lymphocytic leukemia by means of comparing data for 3H-TdR labelling of myeloblast-like cells and 3H-TdR suiciding of cluster-forming cells. The fraction of myelo...

journal_title：Hematological oncology

authors： Gustavsson A,Olofsson T,Olsson I

更新日期：1984-04-01 00:00:00

abstract：:High-dose chemotherapy (HDCT) has a consolidated role in the treatment of patients with refractory or relapsed Hodgkin lymphoma (HL). We report clinical results of 97 HL patients who underwent HDCT for refractory (62 patients) or relapsed (35 patients) diseases in Istituto Europeo di Oncologia, from 1995 to 2009. Trea...

journal_title：Hematological oncology

authors： Cocorocchio E,Peccatori F,Vanazzi A,Piperno G,Calabrese L,Botteri E,Travaini L,Preda L,Martinelli G

更新日期：2013-03-01 00:00:00

abstract：:Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...

journal_title：Hematological oncology

authors： Viviani S,Mazzocchi A,Pavoni C,Taverna F,Rossi A,Patti C,Romano A,Trentin L,Sorasio R,Guidetti A,Gottardi D,Tarella C,Cimminiello M,Zanotti R,Farina L,Ferreri AJM,Galbiati M,Corradini P,Gianni AM,Gallamini A,Ramba

更新日期：2020-10-01 00:00:00

abstract：:Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multi...

journal_title：Hematological oncology

authors： Schütz NP,Ochoa P,Duarte P,Remaggi G,Yantorno S,Corzo A,Zabaljauregui S,Shanley C,Lopresti S,Orlando S,Verri V,Quiroga L,García CA,Fernández V,Fantl D

更新日期：2020-08-01 00:00:00

abstract：:This multicentre study focused on monitoring imatinib mesylate (IMA) trough plasma (Ctrough ) and intracellular (IMA Cintrac ) concentrations in 228 chronic myelogenous leukaemia patients. The median of measured IMA Ctrough in our patient group was 905.8 ng ml (range: 27.7-4628.1 ng/ml). We found a correlation between...

journal_title：Hematological oncology

authors： Racil Z,Razga F,Klamova H,Voglova J,Belohlavkova P,Malaskova L,Potesil D,Muzik J,Zackova D,Polakova KM,Zdrahal Z,Malakova J,Suttnar J,Dyr J,Mayer J

更新日期：2014-06-01 00:00:00

abstract：:There have been an increasing number of reports describing a pivotal role for phosphorylation in cellular responses for cell differentiation and proliferation. We examined an immunocytochemical expression of protein kinase C(PKC) isozymes (type I, II, and III) in 22 leukemia-lymphoma cell lines. Of these cell lines, 2...

journal_title：Hematological oncology

authors： Hojo H,Morimura Y,Abe M,Tominaga K,Nozawa Y,Nakamura N,Ono N,Tasaki K,Yamaguchi Y,Suzuki S

更新日期：1992-11-01 00:00:00

abstract：:Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count ...

journal_title：Hematological oncology

authors： Malik ST,Tucker J,Rohatiner AZ,Brace W,Lister TA

更新日期：1989-11-01 00:00:00

abstract：:Cytotoxic and DNA synthesis inhibitory effects of several iron chelators with different physicochemical properties have been tested in four myeloid leukaemic cell lines (U937, K562, ML2 and HL60). The small lipophilic chelators 8-hydroxyquinoline, tropolone and omadine at 2 X 10(-5) M, caused substantial inhibition of...

journal_title：Hematological oncology

authors： Kontoghiorghes GJ,Piga A,Hoffbrand AV

更新日期：1986-07-01 00:00:00